​

Rhythm Pharmaceuticals (RYTM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RYTM Stock Forecast

Rhythm Pharmaceuticals (RYTM) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $90.00, with a high of $110.00 and a low of $70.00. This represents a 4.11% increase from the last price of $86.45.

$35 $50 $65 $80 $95 $110 High: $110 Avg: $90 Low: $70 Last Closed Price: $86.45

RYTM Stock Rating

Rhythm Pharmaceuticals stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 16 Strong Sell Sell Hold Buy Strong Buy

RYTM Price Target Upside V Benchmarks

TypeNameUpside
StockRhythm Pharmaceuticals4.11%
SectorHealthcare Stocks 18.80%
IndustryBiotech Stocks 54.28%

Price Target Trends

1M3M12M
# Anlaysts3311
Avg Price Target$100.67$100.67$77.00
Last Closing Price$86.45$86.45$86.45
Upside/Downside16.45%16.45%-10.93%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 2548---12
Jun, 2548---12
May, 2537---10
Apr, 25471--12
Mar, 25461--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 10, 2025Leland GershellOppenheimer$110.00$89.0423.54%27.24%
Jul 10, 2025Corinne JohnsonGoldman Sachs$97.00$89.048.94%12.20%
Jul 09, 2025Michael UlzMorgan Stanley$95.00$89.006.74%9.89%
Mar 05, 2025Stifel Nicolaus$78.00$52.9747.25%-9.77%
Mar 03, 2025H.C. Wainwright$70.00$52.4033.59%-19.03%
Jan 01, 2025Dennis DingJefferies$80.00$55.9842.91%-7.46%
Dec 05, 2024Corinne JenkinsGoldman Sachs$66.00$60.029.96%-23.66%
Nov 06, 2024Alan CarrNeedham$64.00$55.7914.72%-25.97%
Nov 06, 2024Corinne JenkinsGoldman Sachs$59.00$55.795.75%-31.75%
Sep 18, 2024Raghuram SelvarajuH.C. Wainwright$64.00$53.1720.37%-25.97%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 10, 2025GuggenheimBuyBuyhold
Mar 18, 2025NeedhamBuyBuyhold
Dec 31, 2024JefferiesBuyinitialise
Dec 05, 2024Goldman SachsBuyBuyhold
Nov 06, 2024Cowen & Co.BuyBuyhold
Nov 06, 2024Goldman SachsBuyBuyhold
Oct 21, 2024GuggenheimBuyinitialise
Sep 18, 2024NeedhamMarket OutperformMarket Outperformhold
Sep 18, 2024H.C. WainwrightBuyinitialise
Sep 17, 2024JMP SecuritiesOutperforminitialise

Financial Forecast

EPS Forecast

$-5 $-2 $1 $4 $7 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.96$-1.37$-3.51$-3.20$-4.34----
Avg Forecast$-3.02$-1.45$-3.53$-3.20$-4.12$-2.46$-0.75$2.25$6.28
High Forecast$-2.67$-1.28$-3.23$-3.16$-3.82$-1.98$0.06$2.74$7.69
Low Forecast$-3.55$-1.70$-4.09$-3.27$-4.39$-2.79$-2.04$1.22$5.49
Surprise %-1.99%-5.52%-0.57%-5.34%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$3.15M$23.64M$77.43M$130.13M----
Avg Forecast$52.97K$3.03M$21.41M$78.80M$126.00M$181.85M$333.83M$602.63M$970.38M
High Forecast$60.18K$3.44M$23.99M$80.69M$127.08M$208.91M$333.83M$602.63M$1.14B
Low Forecast$48.25K$2.76M$20.00M$77.29M$125.06M$164.87M$333.83M$602.63M$876.95M
Surprise %-4.19%10.43%-1.75%3.27%----

Net Income Forecast

$-300M $-150M $0 $150M $300M $450M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-130.73M$-68.01M$-183.08M$-184.68M$-264.57M----
Avg Forecast$-174.03M$-83.43M$-203.78M$-184.68M$-236.88M$-137.49M$-42.97M$114.18M$362.02M
High Forecast$-153.88M$-73.77M$-186.37M$-182.31M$-220.43M$-113.92M$3.61M$158.06M$443.67M
Low Forecast$-204.80M$-98.19M$-235.71M$-188.66M$-253.33M$-161.06M$-117.89M$70.31M$316.71M
Surprise %-24.88%-18.49%-10.16%-11.69%----

RYTM Forecast FAQ

Is Rhythm Pharmaceuticals stock a buy?

Rhythm Pharmaceuticals stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rhythm Pharmaceuticals is a favorable investment for most analysts.

What is Rhythm Pharmaceuticals's price target?

Rhythm Pharmaceuticals's price target, set by 16 Wall Street analysts, averages $90 over the next 12 months. The price target range spans from $70 at the low end to $110 at the high end, suggesting a potential 4.11% change from the previous closing price of $86.45.

How does Rhythm Pharmaceuticals stock forecast compare to its benchmarks?

Rhythm Pharmaceuticals's stock forecast shows a 4.11% upside, underperforming the average forecast for the healthcare stocks sector (18.80%) and underperforming the biotech stocks industry (54.28%).

What is the breakdown of analyst ratings for Rhythm Pharmaceuticals over the past three months?

  • July 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Rhythm Pharmaceuticals’s EPS forecast?

Rhythm Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.46, marking a -43.32% decrease from the reported $-4.34 in 2024. Estimates for the following years are $-0.75 in 2026, $2.25 in 2027, and $6.28 in 2028.

What is Rhythm Pharmaceuticals’s revenue forecast?

Rhythm Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $181.85M, reflecting a 39.75% increase from the reported $130.13M in 2024. The forecast for 2026 is $333.83M, followed by $602.63M for 2027, and $970.38M for 2028.

What is Rhythm Pharmaceuticals’s net income forecast?

Rhythm Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-137M, representing a -48.03% decrease from the reported $-265M in 2024. Projections indicate $-42.973M in 2026, $114.18M in 2027, and $362.02M in 2028.